753 related articles for article (PubMed ID: 33730585)
21. The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma.
Li J; Yu H; Wang X; Ye Y; Fang W; Ding N; Mi L; Ping L; Wang X; Song Y; Zhu J
Cancer Control; 2022; 29():10732748221143881. PubMed ID: 36519740
[TBL] [Abstract][Full Text] [Related]
22. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
[TBL] [Abstract][Full Text] [Related]
23. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Guo H; Zeng D; Zhang H; Bell T; Yao J; Liu Y; Huang S; Li CJ; Lorence E; Zhou S; Gong T; Jiang C; Ahmed M; Yao Y; Nomie KJ; Zhang L; Wang M
Oncogene; 2019 Mar; 38(11):1802-1814. PubMed ID: 30361685
[TBL] [Abstract][Full Text] [Related]
24. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
25. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
26. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
27. Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma.
Ye H; Huang S; Liu Y; Chen Z; Wang M; Jiang VC
J Cell Mol Med; 2022 May; 26(10):3068-3073. PubMed ID: 35352453
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
29. Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
Stewart CM; Michaud L; Whiting K; Nakajima R; Nichols C; De Frank S; Hamlin PA; Matasar MJ; Gerecitano JF; Drullinsky P; Hamilton A; Straus D; Horwitz SM; Kumar A; Moskowitz CH; Moskowitz A; Zelenetz AD; Rademaker J; Salles G; Seshan V; Schöder H; Younes A; Tsui DWY; Batlevi CL
Clin Cancer Res; 2022 Jan; 28(1):45-56. PubMed ID: 34615723
[TBL] [Abstract][Full Text] [Related]
30. T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes.
Dow EC; Liu H; Rice AP
J Cell Physiol; 2010 Jul; 224(1):84-93. PubMed ID: 20201073
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
Rudelius M; Rosenfeldt MT; Leich E; Rauert-Wunderlich H; Solimando AG; Beilhack A; Ott G; Rosenwald A
Haematologica; 2018 Jan; 103(1):116-125. PubMed ID: 29079592
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma.
Choi YJ; Kim DH; Yoon DH; Suh C; Choi CM; Lee JC; Hong JY; Rho JK
Sci Rep; 2019 May; 9(1):7193. PubMed ID: 31076643
[TBL] [Abstract][Full Text] [Related]
33. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Shirsath NP; Manohar SM; Joshi KS
Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
[TBL] [Abstract][Full Text] [Related]
34. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
36. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
Restelli V; Lupi M; Vagni M; Chilà R; Bertoni F; Damia G; Carrassa L
Target Oncol; 2018 Apr; 13(2):235-245. PubMed ID: 29441438
[TBL] [Abstract][Full Text] [Related]
37. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.
Vervoort SJ; Welsh SA; Devlin JR; Barbieri E; Knight DA; Offley S; Bjelosevic S; Costacurta M; Todorovski I; Kearney CJ; Sandow JJ; Fan Z; Blyth B; McLeod V; Vissers JHA; Pavic K; Martin BP; Gregory G; Demosthenous E; Zethoven M; Kong IY; Hawkins ED; Hogg SJ; Kelly MJ; Newbold A; Simpson KJ; Kauko O; Harvey KF; Ohlmeyer M; Westermarck J; Gray N; Gardini A; Johnstone RW
Cell; 2021 Jun; 184(12):3143-3162.e32. PubMed ID: 34004147
[TBL] [Abstract][Full Text] [Related]
38. Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.
Lee SC; Shestov AA; Guo L; Zhang Q; Roman JC; Liu X; Wang HY; Pickup S; Nath K; Lu P; Hofbauer S; Mesaros C; Wang YL; Nelson DS; Schuster SJ; Blair IA; Glickson JD; Wasik MA
Mol Cancer Res; 2019 Jun; 17(6):1365-1377. PubMed ID: 30862686
[TBL] [Abstract][Full Text] [Related]
39. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.
Wu C; de Miranda NF; Chen L; Wasik AM; Mansouri L; Jurczak W; Galazka K; Dlugosz-Danecka M; Machaczka M; Zhang H; Peng R; Morin RD; Rosenquist R; Sander B; Pan-Hammarström Q
Oncotarget; 2016 Jun; 7(25):38180-38190. PubMed ID: 27224912
[TBL] [Abstract][Full Text] [Related]
40. Targeting protein kinase C in mantle cell lymphoma.
Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A
Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
